Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xenon Pharmaceuticals nets $24.3mm in FOPO

Executive Summary

Nasdaq-traded Canadian biotech Xenon Pharmaceuticals Inc. (drug discovery for rare diseases) netted $24.3mm through the public sale of 3.45mm shares (including the overallotment) at $7.50. Selling shareholders also sold 1.15mm shares. The company will use proceeds to fund further development of Phase II XEN801, an SCD1 inhibitor for acne; preclinical development of its Nav1.6 sodium channel inhibitor in childhood epilepsy disorders (for which an IND is expected in mid-2017); as well as continued research activities for its Extreme Genetics platform (for rare human disease target validation) and ion channel drug discovery programs.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies